SUMMARY
# Metabolic Syndrome-Parkinson's Disease Axis Clinical Trial
## Background and Rationale
This innovative clinical trial investigates the bidirectional relationship between metabolic syndrome and Parkinson's disease progression through targeted modulation of the GLP-1 receptor pathway. Emerging epidemiological evidence suggests that metabolic dysfunction, including insulin resistance, obesity, and dyslipidemia, significantly accelerates PD progression and worsens motor and non-motor symptoms. GLP
METHODOLOGY NOTES
**Phase 1: Screening and Baseline Assessment (Weeks -4 to 0)**
• Screen 300 potential participants aged 45-75 with confirmed Parkinson's disease (Hoehn & Yahr stages 1-3) and metabolic syndrome (≥3 ATP III criteria)
• Exclude patients with Type 1 diabetes, severe gastroparesis, or MDS-UPDRS Part III >60
• Obtain comprehensive baseline measurements: MDS-UPDRS Parts I-IV, MOCA cognitive assessment, PDQ-39 quality of life
• Collect metabolic parameters: HbA1c, fasting glucose, lipid panel, HOMA-IR, waist circumference, blood pressure
• Perform neuroimaging: DaTscan SPECT for dopamine transporter density, structural MRI with volumetrics
• Blood biomarkers: IL-6, TNF-α, CRP, alpha-synuclein, GLP-1 levels, insulin sensitivity markers
**Phase 2: Randomization and Treatment Initiation (Week 1)**
• Randomize 200 eligible participants 1:1 to semaglutide 1.0mg weekly vs. matched placebo
• Stratify by baseline HbA1c (<8% vs ≥8%) and disease duration (<5 vs ≥5 years)
• Initiate dose escalation: 0.